JP2010504994A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010504994A5 JP2010504994A5 JP2009530553A JP2009530553A JP2010504994A5 JP 2010504994 A5 JP2010504994 A5 JP 2010504994A5 JP 2009530553 A JP2009530553 A JP 2009530553A JP 2009530553 A JP2009530553 A JP 2009530553A JP 2010504994 A5 JP2010504994 A5 JP 2010504994A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- effective amount
- hydrogen
- formula
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 89
- 229910052739 hydrogen Inorganic materials 0.000 claims description 20
- 239000001257 hydrogen Substances 0.000 claims description 20
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 13
- 239000011612 calcitriol Substances 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 208000013558 Developmental Bone disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010072610 Skeletal dysplasia Diseases 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- AEDMQUAPBVOJNN-UHFFFAOYSA-N [3-[2-[4-[2-(trifluoromethyl)phenoxy]piperidin-1-yl]-1,3-thiazol-5-yl]-1,2,4-oxadiazol-5-yl]methanol Chemical compound O1C(CO)=NC(C=2SC(=NC=2)N2CCC(CC2)OC=2C(=CC=CC=2)C(F)(F)F)=N1 AEDMQUAPBVOJNN-UHFFFAOYSA-N 0.000 claims description 2
- 210000001789 adipocyte Anatomy 0.000 claims description 2
- 210000000577 adipose tissue Anatomy 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 230000004069 differentiation Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 206010025135 lupus erythematosus Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000002374 sebum Anatomy 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 230000037393 skin firmness Effects 0.000 claims description 2
- 230000037067 skin hydration Effects 0.000 claims description 2
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- 230000037303 wrinkles Effects 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 70
- 150000002431 hydrogen Chemical class 0.000 description 2
- OSYUVBVMUWQGDB-ORFZCRMOSA-N C[C@@H](C/C=C/[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O)O Chemical compound C[C@@H](C/C=C/[C@H](C)[C@@H](CC1)[C@@](C)(CCC2)[C@@H]1/C2=C/C=C(C[C@H](C1=C)O)C[C@H]1O)O OSYUVBVMUWQGDB-ORFZCRMOSA-N 0.000 description 1
- 0 C[C@](*)CC=C[C@](C)C(CC1)[C@@](C)(CCC2)[C@@]1C2=CC=C(CC1)C[C@@](*)C1=C Chemical compound C[C@](*)CC=C[C@](C)C(CC1)[C@@](C)(CCC2)[C@@]1C2=CC=C(CC1)C[C@@](*)C1=C 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84880506P | 2006-09-28 | 2006-09-28 | |
| PCT/US2007/079381 WO2008039751A2 (en) | 2006-09-28 | 2007-09-25 | 2-methylene-(20s,25s)-19,27-dinor-(22e)-vitamin d analogs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010504994A JP2010504994A (ja) | 2010-02-18 |
| JP2010504994A5 true JP2010504994A5 (enExample) | 2010-10-21 |
Family
ID=39172159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530553A Pending JP2010504994A (ja) | 2006-09-28 | 2007-09-25 | ２−メチレン−（２０ｓ，２５ｓ）−１９，２７−ジノル−（２２ｅ）−ビタミンｄ類縁体 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8114859B2 (enExample) |
| EP (1) | EP2069296B1 (enExample) |
| JP (1) | JP2010504994A (enExample) |
| AT (1) | ATE552238T1 (enExample) |
| AU (1) | AU2007300211A1 (enExample) |
| CA (1) | CA2662864A1 (enExample) |
| MX (1) | MX2009002944A (enExample) |
| NZ (1) | NZ575159A (enExample) |
| WO (1) | WO2008039751A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8399439B2 (en) * | 2008-07-10 | 2013-03-19 | Wisconsin Alumni Research Foundation | 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs |
| EP2525799B1 (en) * | 2009-10-02 | 2014-09-03 | Wisconsin Alumni Research Foundation | (20s,22e)-2-methylene-19-nor-22-ene-1alpha,25-dihydroxyvitamin d3 analogs |
| CA2824870C (en) * | 2011-06-14 | 2018-08-14 | Wisconsin Alumni Research Foundation | 3-desoxy-2-methylene-19-nor-vitamin d analogs and their uses |
| US9545302B2 (en) | 2013-11-20 | 2017-01-17 | Dermagenesis Llc | Skin printing and auto-grafting |
| US20150140058A1 (en) * | 2013-11-20 | 2015-05-21 | Dermagenesis Llc | Skin printing and auto-grafting |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4486333A (en) * | 1981-04-10 | 1984-12-04 | Felix Sebba | Preparation of biliquid foam compositions |
| US4666634A (en) * | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
| US5086191A (en) * | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
| JP2898882B2 (ja) * | 1993-04-05 | 1999-06-02 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物 |
| US5945410A (en) * | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| SI3146969T1 (en) * | 1999-04-23 | 2018-08-31 | Leo Pharma A/S | Ointment for topical treatment of psoriasis |
| US6806262B2 (en) * | 2000-05-31 | 2004-10-19 | Wisconsin Alumni Research Foundation | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| EP1305946A1 (en) | 2000-07-21 | 2003-05-02 | Koninklijke Philips Electronics N.V. | Method and system for determining a user profile |
| AU7544501A (en) * | 2000-09-08 | 2002-03-22 | Wisconsin Alumni Res Found | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| US6627622B2 (en) * | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| US6566352B1 (en) * | 2002-02-18 | 2003-05-20 | Wisconsin Alumni Research Foudation | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| US20050009792A1 (en) | 2003-07-08 | 2005-01-13 | Deluca Hector F. | (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
| WO2005051323A2 (en) | 2003-11-25 | 2005-06-09 | Wisconsin Alumni Research Foundation | Vitamin d analogs for obesity prevention and treatment |
| WO2006057884A2 (en) * | 2004-11-22 | 2006-06-01 | Wisconsin Alumni Research Foundation | 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES |
| US7528122B2 (en) * | 2006-02-02 | 2009-05-05 | Wisconsin Alumni Research Foundation | Vitamin D analog—NEL, methods and uses thereof |
| NZ570814A (en) * | 2006-04-06 | 2011-11-25 | Wisconsin Alumni Res Found | 2-methylene-1alpha-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof |
-
2007
- 2007-09-25 JP JP2009530553A patent/JP2010504994A/ja active Pending
- 2007-09-25 US US11/860,863 patent/US8114859B2/en not_active Expired - Fee Related
- 2007-09-25 AU AU2007300211A patent/AU2007300211A1/en not_active Abandoned
- 2007-09-25 NZ NZ575159A patent/NZ575159A/en not_active IP Right Cessation
- 2007-09-25 WO PCT/US2007/079381 patent/WO2008039751A2/en not_active Ceased
- 2007-09-25 EP EP07843117A patent/EP2069296B1/en not_active Not-in-force
- 2007-09-25 CA CA002662864A patent/CA2662864A1/en not_active Abandoned
- 2007-09-25 MX MX2009002944A patent/MX2009002944A/es not_active Application Discontinuation
- 2007-09-25 AT AT07843117T patent/ATE552238T1/de active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505739A5 (enExample) | ||
| JP2010504995A5 (enExample) | ||
| JP2009532458A5 (enExample) | ||
| JP2008520689A5 (enExample) | ||
| JP2008520703A5 (enExample) | ||
| JP2005529878A5 (enExample) | ||
| JP2010504994A5 (enExample) | ||
| CA2420026A1 (en) | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications | |
| JP2008520691A5 (enExample) | ||
| Drucker et al. | Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology | |
| Turner et al. | Refractory symptoms successfully treated with leukotriene inhibition in a child with systemic mastocytosis. | |
| TW201936567A (zh) | 發炎性疾病或骨病之預防或治療劑及醫藥組成物 | |
| CA2588410A1 (en) | 2-methylene-19-nor-1.alpha.-hydroxy-17-ene-homopregnacalciferol and its uses | |
| CA2588415A1 (en) | 2-methylene-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and its uses | |
| JP2011527699A5 (enExample) | ||
| JP2011527695A5 (enExample) | ||
| JP2008520704A5 (enExample) | ||
| JP2009533483A5 (enExample) | ||
| JP2011527696A5 (enExample) | ||
| JP2008520690A5 (enExample) | ||
| CA2531505A1 (en) | (20s)-1.alpha.-hydroxy-2-methylene-19-nor-vitamin d3 and its uses | |
| JP2008530110A5 (enExample) | ||
| JP2008520709A5 (enExample) | ||
| JP2004521951A5 (enExample) | ||
| JP2013522369A5 (enExample) |